Current location:Home>Disease>

 Pub date
2007-01-14

FDA warns blood thinner linked to clots - Heart Health - MSNBC.com

Source:MSNBC NEWS  Editor:MSNBC NEWS  Read:

FDA warns blood thinner linked to clots - Heart Health - MSNBC.com

FDA warns blood thinner linked to clots

Risk increases after ending Heparin, drug manufacturer says

WASHINGTON - The Food and Drug Administration and Baxter International Inc. have notified doctors that the drug Heparin could be linked to thrombosis or blood clots in patients several weeks after they stop taking it, the agency said Friday.

The FDA said it revised the warnings section of the prescribing information for Heparin, a blood thinner, because of the possibility of delayed onset of thrombocytopenia and thrombosis. The agency described that as a "serious antibody-mediated reaction resulting from irreversible aggregation of platelets."

"Thrombotic events may be the initial presentation for heparin-induced thrombocytopenia and thrombosis which can occur up to several weeks after the discontinuation of heparin therapy," the FDA said in a notice.

Baxter spokeswoman Erin Gardiner said the company asked the FDA to add the new labeling language to reflect current medical literature on the drug, as a reminder to doctors to monitor patients for the potential effects. Heparin is available in generic form and sold by other companies as well.

 Click for related content

Dropping statins may increase heart attack risk

The move was not prompted by any recent increase in adverse events or complaints about the product, she added.

The prescribing information for Heparin also includes the warning that the drug may cause pulmonary embolism, cerebral blood clots, strokes, skin necrosis, and gangrene in arms and legs that could lead to amputation and possible death.

Heparin is typically administered intravenously to thin a patient's blood when there is a danger of clotting.

The drug generates annual sales of about $30 million, Baxter said.

Copyright 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters.


{/dede:arclist}

More Other Information

ation.com/pagead/show_ads.js">